Core Insights - VIO Med Spa has been selected as a key franchise partner for Obagi Medical's Aesthetics Leadership with Obagi's Hyaluronic Acid (ALOHA) Program due to its commitment to clinical excellence and innovative aesthetic care [1][4] - The partnership aims to leverage VIO Med Spa's strengths in injectables and patient education to generate real-world evidence on the performance of Obagi® saypha® MagIQ™ filler [2][3] Company Overview - Obagi Medical is a leading innovator in physician-dispensed skincare with over 35 years of experience, known for addressing various skin concerns and recognized as the fastest-growing professional skincare brand in the U.S. in 2024 [6][10] - VIO Med Spa is a nationally recognized franchise specializing in advanced aesthetic and wellness treatments, focusing on clinical excellence and patient safety across its numerous locations [7] Program Details - The ALOHA Program will conduct a structured, multi-site assessment of the filler, emphasizing both clinical performance and patient experience while providing comprehensive protocols to enhance satisfaction and outcomes [3][4] - The program will kick off with a two-day immersive training for the VIO network, aimed at standardizing data collection across participating locations [3]

Company Overview - Star Group, L.P. is a leading home energy distributor and services provider, specializing in the sale of home heating products and services to residential and commercial customers [3] - The company is recognized as the nation's largest retail distributor of home heating oil based on sales volume, serving customers primarily in the Northeast and Mid-Atlantic U.S. regions [3] Upcoming Financial Results - Star Group will release its fiscal 2026 first quarter results after the close of trading on February 4, 2026 [1] - A webcast and conference call will be hosted by the management team on February 5, 2026, at 11:00 a.m. Eastern Time to review the results for the three months ended December 31, 2025 [1][2] Contact Information - For investor relations, Star Group can be contacted at 203/328-7310, and Chris Witty from Darrow Associates, Inc. is available at 646/438-9385 or via email at cwitty@darrowir.com [5]

Core Insights - ALX Oncology announced new data from a Phase 1b/2 clinical trial evaluating the CD47-inhibitor evorpacept in combination with Jazz Pharmaceuticals' ZIIHERA® for metastatic breast cancer, reinforcing CD47 as a predictive biomarker for treatment response [1][2] Group 1: Clinical Trial Findings - The Phase 1b/2 trial demonstrated promising anti-tumor activity and a manageable safety profile in heavily pretreated HER2-positive breast cancer patients, with a median of six prior therapies [2] - The combination treatment achieved a confirmed objective response rate (cORR) of 56% (5 out of 9 patients) and a median progression-free survival (mPFS) of 7.4 months [2] - Additional exploratory analysis indicated that responses were largely restricted to patients with higher CD47 expression, supporting findings from the ASPEN-06 trial [3] Group 2: Future Directions - The company plans to adopt a biomarker-driven approach for patient selection in future trials involving evorpacept and HER2-targeted agents [2] - Full biomarker analysis from the Phase 1b/2 trial has been submitted for presentation at an upcoming scientific congress [4] Group 3: Company Overview - ALX Oncology is a clinical-stage biotechnology company focused on developing novel therapies for cancer treatment, with evorpacept as a lead candidate [5] - The company is also advancing a second pipeline candidate, ALX2004, which is currently in a Phase 1 trial for EGFR-expressing solid tumors [5]

Core Viewpoint - China Medical System Holdings Limited's subsidiary, Dermavon Holdings Limited, received approval for ruxolitinib phosphate cream, the first targeted drug for non-segmental vitiligo in China, addressing a significant unmet clinical need for over 10 million patients [1][4]. Group 1: Product Approval and Market Potential - Ruxolitinib phosphate cream is the first drug approved by both the U.S. FDA and the European Medicines Agency for repigmentation in non-segmental vitiligo [2]. - The product has been prescribed to over 7,000 patients at Boao Super Hospital and is available in more than twenty hospitals across major cities in China, indicating strong clinical demand [2]. - The approval is expected to enhance Dermavon's product portfolio in skin treatment, potentially synergizing with existing products like ILUMETRI and Hirudoid [4]. Group 2: Clinical Efficacy and Safety - In overseas Phase III clinical studies, 29.9% of patients achieved at least 75% improvement in the Facial Vitiligo Area Score Index after 24 weeks of treatment, compared to 7.5% and 12.9% in placebo groups [3]. - Real-world studies in China showed consistent positive efficacy with no new safety events reported, indicating a favorable safety profile for the product [3]. Group 3: Future Developments - The Phase III clinical trial for ruxolitinib phosphate cream in treating mild to moderate atopic dermatitis has also shown positive results, with an NDA actively being pursued for this indication [5]. - The approval of ruxolitinib phosphate cream fills a significant gap in targeted treatment options for vitiligo, which affects approximately 10.3 million patients in China [6].

Raymond James engaged as financial advisorReduction in force implemented NEW YORK, Jan. 30, 2026 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today announced that it has retained Raymond James & Associates, Inc. to serve as exclusive financial advisor to assist the company in its previously announced exploration of strategic alternatives. The company also announced that it is impleme ...

Financial Performance - Sierra Bancorp declared a regular quarterly cash dividend of $0.26 per share, marking a 4% increase from the previous quarter's dividend of $0.25 per share [1] - The dividend will be paid on February 17, 2026, to shareholders of record as of February 9, 2026 [1] - The company has paid regular cash dividends every year since 1987, with the current announcement representing the 108th consecutive quarterly cash dividend [1] Company Overview - Sierra Bancorp is the parent company of Bank of the Sierra, which is one of the largest independent banks in the South San Joaquin Valley [2] - Bank of the Sierra offers a wide range of retail and commercial banking services through full-service branches in several counties, including Tulare, Kern, Kings, Fresno, Ventura, San Luis Obispo, and Santa Barbara [2] - In 2025, Bank of the Sierra was recognized as one of the strongest community banks in the country, receiving a 5-star rating from Bauer Financial [2]

ZEELAND, Mich., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Gentex Corporation (NASDAQ: GNTX), a leading supplier of digital vision, connected car, dimmable glass, fire protection technologies, medical devices, and consumer electronics, today reported financial results for the fourth quarter and calendar year ended December 31, 2025. Fourth Quarter and Calendar Year 2025 Highlights: Fourth Quarter 2025 Net Sales: Consolidated $644.4 million; Core Gentex (ex-VOXX) $541.0 millionGross Margin: Consolidated 34.8%; Core G ...

HONOLULU, Jan. 30, 2026 (GLOBE NEWSWIRE) -- First Hawaiian, Inc. (NASDAQ:FHB), (“First Hawaiian” or the “Company”) today reported financial results for its quarter ended December 31, 2025. “I’m happy to report that First Hawaiian finished 2025 with another strong quarter,” said Bob Harrison, Chairman, President, and CEO. “Loans grew, retail and commercial deposits grew, and we remained the most profitable bank in the state.” On January 28, 2026, the Company’s Board of Directors declared a quarterly cash div ...

PARAMUS, NJ, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics (“Polaryx” or the “Company”) a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (“LSDs”), today announced that shares of the Company’s common stock have been approved for listing on the Nasdaq Capital Market (“Nasdaq”) under the ticker symbol “PLYX”. Shares of Polaryx common stock are expected to commence ...

BELVIDERE, NJ, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Edible Garden AG Incorporated (“Edible Garden” or the “Company”) (Nasdaq: EDBL, EDBLW), a leading provider of controlled environment agriculture (CEA) solutions and sustainable, locally grown organic produce,  today announced a planned reverse stock split of its shares of common stock at a ratio of 1-for-10. The reverse stock split will take effect as of 12:01 a.m. ET, on February 3, 2026, and shares of Edible Garden will trade on a post-split basis on Nasdaq ...